For example, the detection of somatically acquired mutations in the KRAS gene has been shown to interfere with the efficacy of new targeted treatments (EGFR-targeted mAbs) for bowel, head and neck, and lung cancers such that the treatment is only recommended to individuals harbouring the wild-type KRAS (52). Here, KRAS is linked to lung carcinoma.